Cencora Inc. (COR)vsNovartis AG ADR (NVS)
COR
Cencora Inc.
$286.13
-0.29%
HEALTHCARE · Cap: $55.67B
NVS
Novartis AG ADR
$155.41
+0.19%
HEALTHCARE · Cap: $296.54B
Smart Verdict
WallStSmart Research — data-driven comparison
Cencora Inc. generates 481% more annual revenue ($328.68B vs $56.58B). NVS leads profitability with a 23.9% profit margin vs 0.8%. COR appears more attractively valued with a PEG of 0.61. COR earns a higher WallStSmart Score of 64/100 (C+).
COR
Buy64
out of 100
Grade: C+
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-58.6%
Fair Value
$180.37
Current Price
$286.13
$105.76 premium
Margin of Safety
-69.7%
Fair Value
$91.58
Current Price
$155.41
$63.83 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 75 in profit
Earnings expanding 128.3% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Growing faster than its price suggests
Generating 1.2B in free cash flow
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Trading at 16.4x book value
3.8% revenue growth
0.8% margin — thin
Operating margin of 1.7%
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : COR
The strongest argument for COR centers on Return on Equity, EPS Growth, Altman Z-Score. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : COR
The primary concerns for COR are Price/Book, Revenue Growth, Profit Margin. Debt-to-equity of 3.65 is elevated, increasing financial risk. Thin 0.8% margins leave little buffer for downturns.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
COR profiles as a value stock while NVS is a declining play — different risk/reward profiles.
COR carries more volatility with a beta of 0.59 — expect wider price swings.
COR is growing revenue faster at 3.8% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
COR scores higher overall (64/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cencora Inc.
HEALTHCARE · MEDICAL DISTRIBUTION · USA
CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?